


CLAIMS

1. A solid form of a compound of formula I-2:



I-2

- wherein the form is selected from the group consisting of: Compound I-2 free base, Compound I-2 • HCl, Compound I-2 • HCl • H₂O, Compound I-2 • HCl • 2H₂O, and Compound I-2 • 2-hydrochloric acid.
2. The solid form of claim 1, wherein the form is Compound I-2 free base.
3. The solid form of claim 1, wherein the form is crystalline compound I-2 free base.
4. The solid form of claim 3, having a monoclinic crystal system, having a P2₁/n space group, and having the following unit cell dimensions in Å when measured at 120K:
a = 8.9677 (1) Å
b = 10.1871 (1) Å
c = 24.5914 (3) Å.
5. The solid form of claim 3, characterized by a weight loss of from about 1.9 % in a temperature range of from about 25 °C to about 215 °C.
6. The solid form of claim 3, characterized by one or more peaks expressed in 2-theta ± 0.2 at about 14.2, 25.6, 18.1, 22.0, and 11.1 degrees in a X-ray powder diffraction pattern obtained using Cu K alpha radiation.
7. The solid form of claim 3, characterized as having an X-ray powder diffraction pattern substantially the same as that shown in Figure 1a.

8. The solid form of claim 1, wherein the form is Compound I-2 • HCl.
9. The solid form of claim 1, wherein the form is crystalline Compound I-2 • HCl.
10. The solid form of claim 9, wherein the compound:HCl are in a ratio of 1:1.
11. The solid form of claim 9, having a monoclinic crystal system, having a $P2_1/n$ space group, and having the following unit cell dimensions in Å when measured at 120K:
a = 5.3332 (2) Å
b = 35.4901 (14) Å
c = 13.5057 (5) Å.
12. The solid form of claim 9, characterized by a weight loss of from about 1.1 % in a temperature range of from about 25 °C to about 100 °C, and about 0.8% from 110 °C to about 240 °C.
13. The solid form of claim 9, characterized by one or more peaks expressed in 2-theta $\pm$ 0.2 at about 13.5, 28.8, 15.0, 18.8, and 15.4 degrees in an X-ray powder diffraction pattern obtained using Cu K alpha radiation.
14. The solid form of claim 9, characterized by one or more peaks at about 171.7, 153.4, 132.9, 31.8, and 15.7 ppm in solid state ^{13}C NMR.
15. The solid form of claim 9, characterized as having an X-ray powder diffraction pattern substantially the same as that shown in Figure 1b.
16. The solid form of claim 1, wherein the form is Compound I-2•2-hydrochloric acid.
17. The solid form of claim 1, wherein the form is Crystalline Compound I-2• 2HCl.
18. The solid form of claim 17, wherein the compound:HCl are in a ratio of 1:2.

19. The solid form of claim 17, characterized by one or more peaks at about 15.1, 18.5, 11.5, 13.1, and 5.7 in an X-ray powder diffraction pattern.
20. The solid form of claim 17, characterized as having an X-ray powder diffraction pattern substantially the same as that shown in Figure 1c.
21. The solid form of claim 17, having a monoclinic crystal system, having a $P2_1/n$ space group, and having the following unit cell dimensions in Å when measured at 120K:
a = 5.3332 (2) Å
b = 35.4901 (14) Å
c = 13.5057 (5) Å.
22. The solid form of claim 17, characterized by a weight loss of from about 7% in a temperature range of from about 25 °C to about 188 °C.
23. The solid form of claim 17, characterized by one or more peaks at about 15.1, 18.5, 11.5, 13.1, and 5.7 degrees in an X-ray powder diffraction pattern obtained using Cu K alpha radiation.
24. The solid form of claim 17, characterized as having an X-ray powder diffraction pattern substantially the same as that shown in Figure 1c.
25. The solid form of claim 17, characterized by one or more peaks at about 166.5, 137.6, 136.1, 34.2, and 16.4 ppm in solid state ^{13}C NMR.
26. The solid form of claim 1, wherein the form is Compound I-2• 2HCl • H₂O.
27. The solid form of claim 1, wherein the form is Crystalline compound I-2• 2HCl • H₂O.
28. The solid form of claim 27, wherein the compound:HCl:H₂O are in a ratio of 1:2:1.
29. The solid form of claim 27 characterized by a weight loss of from about 2.9% in a temperature range of from about 25 °C to about 100 °C and a weight loss of about 0.6% from about 100 °C to about 222 °C.

30. The solid form of claim 27 characterized by one or more peaks at about 6.6, 19.5, 24.7, 8.1, and 11.2 degrees in a X-ray powder diffraction pattern obtained using Cu K alpha radiation.
31. The solid form of claim 27, characterized as having an X-ray powder diffraction pattern substantially the same as that shown in Figure 1d.
32. The solid form of claim 1, wherein the form is Compound I-2 • HCl• 2H₂O.
33. The solid form of claim 1, wherein the form is Crystalline compound I-2 • HCl• 2H₂O.
34. The solid form of claim 33 wherein the compound:HCl:H₂O are in a ratio of 1:1:2.
35. The solid form of claim 33 characterized by a weight loss of from about 6% in a temperature range of from about 25 °C to about 100 °C.
36. The solid form of claim 33 characterized by one or more peaks at about 26.6, 7.6, 6.3, 23.3, and 24.6 degrees in a X-ray powder diffraction pattern obtained using Cu K alpha radiation.
37. A pharmaceutical composition comprising a solid form of claim 1 and a pharmaceutically acceptable carrier.
38. The solid form of claim 1 for use in the treatment of cancer.
39. Use of the solid form of claim 1 in the manufacture of a medicament for the treatment of cancer.
40. The use according to claim 39, wherein the cancer is pancreatic cancer or non small cell lung cancer.